Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Validation of a CYP2D6 genotyping panel on the NanoChip Molecular Biology Workstation.

Clinical chemistry - 1 May 2007

Lee Hong-Kee, Lewis Lionel D, Tsongalis Gregory J, Schur Bernard C, Jannetto Paul J, Wong Steven H, Yeo Kiang-Teck J

Abstract excerpt

BACKGROUND: CYP2D6 is a highly polymorphic phase I enzyme that metabolizes 20%-25% of clinically used drugs. The objective of this study was to validate a CYP2D6 genotyping assay with the NanoChip Molecular Biology Workstation. METHODS: We genotyped 200 anonymized human DNA samples with the Pyrosequencing platform at the Medical College of Wisconsin and with the NanoChip platform at Dartmouth Medical School. We...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Aged
Share to Cytochrome P-450 CYP2D6

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Duplication

Share to Nanotechnology

Share to Oligonucleotide Array Sequence Analysis

Share to Reproducibility of Results

Share to Sequence Deletion

Source

Identifiers

PMID: 17363417
DOI: 10.1373/clinchem.2006.081539

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Validation of a CYP2D6 genotyping panel on the NanoChip Molecular Biology Workstation.PMID 17363417Read ↗

DNA microarray technology in the clinical environment: the AmpliChip CYP450 test for CYP2D6 and CYP2C19 genotyping.Semantic proximity Read ↗

Characterization of 107 genomic DNA reference materials for CYP2D6, CYP2C19, CYP2C9, VKORC1, and UGT1A1: a GeT-RM and Association for Molecular Pathology collaborative project.Semantic proximity Read ↗

Nanopore sequencing of the pharmacogene CYP2D6 allows simultaneous haplotyping and detection of duplicationsSemantic proximity Read ↗

Comparison of performance of three commercial platforms for warfarin sensitivity genotyping.Semantic proximity Read ↗

Microelectronic array system for molecular diagnostic genotyping: Nanogen NanoChip 400 and molecular biology workstation.Semantic proximity Read ↗

Characterization of a complex CYP2D6 genotype that caused an AmpliChip CYP450 Test no-call in the clinical setting.Semantic proximity Read ↗

A Multiplex Pharmacogenetics Assay using the MinION Nanopore Sequencing DeviceSemantic proximity Read ↗

Validation of methodology for efficient genotyping of CYP2D6 and CYP2C19Semantic proximity Read ↗

A novel simple method for determining CYP2D6 gene copy number and identifying allele(s) with duplication/multiplication.Semantic proximity Read ↗

Resolution of a clinical AmpliChip CYP450 Test™ no call: discovery and characterization of novel CYP2D6*1 haplotypes.Semantic proximity Read ↗

Cas9 targeted nanopore sequencing with enhanced variant calling improves <i>CYP2D6</i> - <i>CYP2D7</i> hybrid allele genotypingSemantic proximity Read ↗

Evaluation of electronic microarrays for genotyping factor V, factor II, and MTHFR.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.